Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
556.2(c) 553(c) 560(c) 560.5(c) 570.9(c) Last
1 961 550 1 876 209 1 717 878 1 427 006 1 535 012 Volume
+0.07% -0.58% +1.27% +0.09% +1.86% Change
More quotes
Estimated financial data (e)
Sales 2021 133 B 21 099 M 21 099 M
Net income 2021 44 318 M 7 017 M 7 017 M
Net cash position 2021 6 391 M 1 012 M 1 012 M
P/E ratio 2021 29,7x
Yield 2021 1,70%
Sales 2022 145 B 22 916 M 22 916 M
Net income 2022 48 226 M 7 635 M 7 635 M
Net cash position 2022 11 403 M 1 805 M 1 805 M
P/E ratio 2022 26,6x
Yield 2022 1,86%
Capitalization 1 309 B 207 B 207 B
EV / Sales 2021 9,78x
EV / Sales 2022 8,97x
Nbr of Employees 45 157
Free-Float 69,8%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
Sector
Pharmaceuticals
Calendar
08/05 | 01:30amEarnings Release
More about the company
Ratings of Novo Nordisk A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about NOVO NORDISK A/S
07/19NOVO NORDISK A/S : – Share repurchase programme
AQ
07/19NOVO NORDISK : Barclays maintains a Buy rating
MD
07/13PROTHENA : Oppenheimer Adjusts Prothena PT to $76 From $54, Maintains Outperform..
MT
07/12NOVO NORDISK A/S : to buy Prothena's heart drug in deal worth up to $1.2 billion
RE
07/12PROTHENA : Sells ATTR Amyloidosis Program to Novo Nordisk
MT
07/12NOVO NORDISK A/S : To Acquire Rights To Prothena's ATTR Amyloidosis Program
MT
07/12NOVO NORDISK : Jefferies gives a Sell rating
MD
07/09President Biden's Competition Order to Crack Down on Antitrust Practices by B..
MT
07/07NOVO NORDISK A/S : Parent Acquires Minority Stake in Availity
MT
07/07SYNACT PHARMA : Appoints New Chief Medical Officer
MT
07/07NOVO NORDISK : Goldman Sachs gives a Buy rating
MD
07/07SYNACT PHARMA : Appoints Anders Dyhr Toft, MD, Ph.D., as Chief Medical Officer
AQ
07/06NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
07/05NOVO NORDISK A/S : – Share repurchase programme
AQ
06/30NOVO NORDISK : Deutsche Bank reiterates its Buy rating
MD
More news
News in other languages on NOVO NORDISK A/S
07/12NOVO NORDISK : acquisition d'un programme auprès de Prothena
07/09PORTEFEUILLE ETF : Un portefeuille défensif avec une touche de bleu et de vert
07/07NOVO NORDISK : un investissement stratégique aux USA
07/05NOVO NORDISK : rachat d'actions pour 3,3 milliards de DKK
07/05LE TOUR D’HORIZON DES ETF  : une bonne décharge, des valeurs pépères et du bitco..
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 2020
A good level to buy
BUY
More Stock Trading Analysis
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Last Close Price 570,90 DKK
Average target price 485,37 DKK
Spread / Average Target -15,0%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S33.81%188 446
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246